Fennec Pharma
Highly Engaged Employees
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
68 Tw Alexander Research Triangle Park D...Phone Number
(919) 636-4530Website
www.fennecpharma.comRevenue
$44.6 MillionStock Symbol
FENCIndustry
About Fennec Pharma
Fennec Pharma Org Chart
Is Fennec Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Fennec Pharma had a recent Job posting/layoffs
Check if Fennec Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Fennec Pharma is spiking on competitors!
Fennec Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Fennec Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Fennec Pharma has new funding data
Product Launch: Get notified when Fennec Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Fennec Pharma
Recommended Actions
Find VP level buyers at Fennec Pharma
Find 3 more new buyers
Compare Similar Companies to Fennec Pharma
Compare insights from companies similar to Fennec Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Fennec Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Fennec Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Fennec Pharma.
Fennec Pharma financials insights
Gather financial insights about Fennec Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Private Equity
$45M
Fennec Pharma Tech Stack
A closer look at the technologies used by Fennec Pharma
Most Recent Scoops
Fennec Pharma News & Media
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of stock option awards (“Stock Options”) to purchase an aggregate of 50,000 of the Company’s common shares to three new non-executive employees of the Company with a grant date of May 18, 2026Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
FENNEC PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEFennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients –
Top Manufacturing Companies
Frequently Asked Questions Regarding Fennec Pharma
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina, that specializes in developing and commercializing therapies to reduce the risk of hearing loss caused by platinum-based chemotherapy, particularly in pediatric patients. Its flagship product, PEDMARK®, a formulation... Read More